CELLTECH HALVES LOSSES IN FISCAL 1991

10 February 1992

The Celltech Group, which claims to be the largest independent biotechnology company in the UK, announced that it has halved its pretax losses for the year ended September 30, 1991. The loss on ordinary activities before tax was L6.6 million ($11.7 million) in 1991, down from L12.5 million in the previous year. Turnover for the year was just over L17 million, down 14.2% on 1990. Celltech's operating loss for the year was L9.4 million, down from L16.7 million in 1990. The biologics division, which is made up of Celltech's manufacturing and trading operations, increased its contribution to operating profit from

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight